Roivant Sciences Ltd. (NASDAQ:ROIV) Shares Sold by DAVENPORT & Co LLC

DAVENPORT & Co LLC lowered its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 38.7% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 160,140 shares of the company's stock after selling 101,300 shares during the quarter. DAVENPORT & Co LLC's holdings in Roivant Sciences were worth $1,894,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the stock. Gladius Capital Management LP bought a new position in Roivant Sciences in the 3rd quarter valued at $35,000. US Bancorp DE grew its position in Roivant Sciences by 146.5% in the 3rd quarter. US Bancorp DE now owns 3,278 shares of the company's stock valued at $38,000 after acquiring an additional 1,948 shares during the last quarter. GAMMA Investing LLC grew its position in Roivant Sciences by 57.0% in the 4th quarter. GAMMA Investing LLC now owns 3,548 shares of the company's stock valued at $42,000 after acquiring an additional 1,288 shares during the last quarter. Quarry LP grew its position in Roivant Sciences by 50.0% in the 3rd quarter. Quarry LP now owns 7,500 shares of the company's stock valued at $87,000 after acquiring an additional 2,500 shares during the last quarter. Finally, Blue Trust Inc. lifted its holdings in shares of Roivant Sciences by 550.1% in the 4th quarter. Blue Trust Inc. now owns 7,879 shares of the company's stock worth $91,000 after buying an additional 6,667 shares during the period. Institutional investors own 64.76% of the company's stock.

Insider Buying and Selling

In other Roivant Sciences news, Director Sciences Ltd. Roivant bought 16,845,010 shares of Roivant Sciences stock in a transaction that occurred on Monday, January 13th. The shares were bought at an average cost of $20.00 per share, with a total value of $336,900,200.00. Following the transaction, the director now directly owns 96,650,341 shares of the company's stock, valued at approximately $1,933,006,820. This represents a 21.11 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Eric Venker sold 100,000 shares of the company's stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $11.32, for a total value of $1,132,000.00. Following the transaction, the chief operating officer now directly owns 606,525 shares in the company, valued at $6,865,863. This represents a 14.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,942,629 shares of company stock worth $23,034,486 in the last three months. 7.90% of the stock is owned by insiders.

Analysts Set New Price Targets

ROIV has been the subject of several research reports. Cantor Fitzgerald upgraded Roivant Sciences to a "strong-buy" rating in a report on Thursday, January 30th. HC Wainwright reiterated a "buy" rating and issued a $18.00 target price on shares of Roivant Sciences in a report on Wednesday, November 13th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $17.93.

Roivant Sciences Stock Up 0.2 %

Shares of NASDAQ ROIV traded up $0.02 during mid-day trading on Friday, reaching $10.89. 5,641,474 shares of the company were exchanged, compared to its average volume of 3,850,469. The stock has a market cap of $7.93 billion, a price-to-earnings ratio of 1.93 and a beta of 1.25. Roivant Sciences Ltd. has a 1 year low of $9.76 and a 1 year high of $13.06. The firm has a 50-day moving average of $11.51 and a 200 day moving average of $11.59.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.